Combination erythropoietin-hydroxyurea therapy in sickle cell disease: Experience from the National Institutes of Health and a literature review

Haematologica

Volumn 91, Issue 8, 2006, Pages 1076-1083

  Little, Jane A ^a,b   McGowan, Vicki R ^b   Kato, Gregory J ^b   Partovi, Kristine S ^b   Feld, Jordan J ^c   Maric, Irina ^d   Martyr, Sabrina ^b   Taylor VI, James G ^b   Machado, Roberto F ^d   Heller, Theo ^c   Castro, Oswaldo ^e   Gladwin, Mark T ^b,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e HOWARD UNIVERSITY   (United States)

Author keywords

Erythropoietin; Hydroxyurea; Pulmonary hypertension; Sickle cell disease

Indexed keywords

DARBEPOIETIN; ERYTHROPOIETIN; HYDROXYUREA; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

BONE PAIN; CYTOPENIA; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; PULMONARY HYPERTENSION; PURE RED CELL ANEMIA; RETICULOCYTE; RETINOPATHY; REVIEW; SICKLE CELL ANEMIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VEIN OCCLUSION;

ANEMIA, SICKLE CELL; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATOCRIT; HUMANS; HYDROXYUREA; NATIONAL INSTITUTES OF HEALTH (U.S.); TREATMENT OUTCOME; UNITED STATES;

EID: 33746942243     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Schechter A, Noguchi C, Rodgers G,. Sickle Cell Disease. In: G. Stamatoyannopoulos, et al., eds. The Molecular Basis of Blood Diseases, 1987, W.B. Saunders: Philadelphia, PA, USA. p. 179-218.
2. Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Rev 2003;17:167-78.
3. Ballas SK, Marcolina MJ. Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state. Hemoglobin 2000;24:277-86.
4. May A, Huehns ER. The concentration dependence of the oxygen affinity of haemoglobin S. Br J Haematol 1975;30: 317-35.
5. Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree or anemia. Blood 1986;67:46-9.
6. Bunn HF, Briehl RW. The interaction of 2,3-diphosphoglycerate with various human hemoglobins. J Clin Invest 1970;49:1088-95.
7. Young RC Jr, Rachal RE, Del Pilar Aguinaga M, Nelson BL, Kim BC, Winter WP, et al. Automated oxyhemoglobin dissociation curve construction to assess sickle cell anemia therapy. J Natl Med Assoc 2000;92:430-5.
8. Camaschella C, Gonella S, Calabrese R, Vischia F, Roetto A, Graziadei G, et al. Serum erythropoietin and circulating transferrin receptor in thalassemia intermedia patients with heterogeneous genotypes. Haematologica 1996; 81:397-403.
9. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-65.
10. Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. Hematol J 2000;5:295-300.
11. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
13. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification, in National Kidney Foundation Kidney Disease Outcome Quality Intitiative. 2002.
14. Morgan AG, Gruber CA, Serjeant GR. Erythropoietin and renal function in sickle-cell disease. Br Med J (Clin Res Ed) 1982;285:1686-8.
15. Sklar AH, Campbell H, Caruana RJ, Lightfoot BO, Gaier JG, Milner P. A population study of renal function in sickle cell anemia. Int J Artif Organs 1990;13:231-6.
16. Sklar AH, Perez JC, Harp RJ, Caruana RJ. Acute renal failure in sickle cell anemia. Int J Artif Organs 1990;13:347-51.
17. Scheinman JI. Sickle cell disease and the kidney. Semin Nephrol 2003;23: 66-76.
18. Etteldorf JN, Smith JD, Tuttle AH, Diggs LW. Renal hemodynamic studies in adults with sickle cell anemia. Am J Med 1955;18:243-8.
19. Allon M, Lawson L, Eckman JR, Delaney V, Bourke E. Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int 1988;34:500-6.
20. Herrera J, Avila E, Marin C, Rodriguez-Iturbe B. Impaired creatinine secretion after an intravenous creatinine load is an early characteristic of the nephropathy of sickle cell anaemia. Nephrol Dial Transplant 2002;17:602-7.
21. Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D. Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. Eur J Haematol 1996;56: 326-8.
22. Roger SD, Macdougall IC, Thuraisingham RC, Raine AE. Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 1991;325:1175-6.
23. Steinberg MH. Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 1991;324:1369-70.
24. Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J. Effect or recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 1992;7:817-21.
25. McGlave PB, Zanjani ED. Erythropoietin and hemoglobin switching. Tex Rep Biol Med 1980;40:125-35.
26. Al-Khatti A, Veith RW, Papayannopoulou T, Fritsch EF, Goldwasser E, Stamatoyannopoulos G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987; 317:415-20.
27. Stamatoyannopoulos G, Veith R, Al-Khatti A, Fritsch EF, Goldwasser E, Papayannopoulou T. On the induction of fetal hemoglobin in the adult; stress erythropoiesis, cell cycle-specific drugs, and recombinant erythropoietin. Prog Clin Biol Res 1987;251:443-53.
28. Miller JL. Signaled expression of fetal hemoglobin during development. Transfusion, 2005;45:1229-32.
29. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990;323:366-72.
30. Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood 1993;81:9-14.
31. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993;328:73-80.
32. el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, et al. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. Acta Haematol 1995;94:128-34.
33. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci USA 1993; 90:5039-43.
34. Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood 1985;65: 183-9.
35. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
36. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11-6.
37. McKerrell TD, Cohen HW, Billett HH. The older sickle cell patient. Am J Hematol 2004;76:101-6.
38. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
39. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-51.
40. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005;84:363-76.
41. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
42. NIDDK, National Kidney Disease Education Program MDRD GFR Calculator. 2005.
43. al-Momen AK. Recombinant human erythropoietin induced rapid healing or a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol 1991;86:46-8.
44. Brooks BJ Jr, Hanson DS, Cryer PA, Hubbard WJ, Hooper D. Erythropoietin therapy for sickle cell anemia in Jehovah's Witnesses. South Med J 1991;84:1416-7.
45. el-Hazmi MA, al-Momen A, Warsy AS, Kandaswamy S, Huraib S, Harakati M, et al. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin. Acta Haematol 1995;93:57-61.
46. Darbepoietin α, in American Hospital Formulary Service (AHFS) Drug Information, G.K. McEvoy ed. 2004, American Society of Health-System Pharmacists: Bethesda, MD, USA. p. 1455-7.
47. Usami S, Chien S, Scholtz PM, Bertles JF. Effect of deoxygenation on blood rheology in sickle cell disease. Microvasc Res 1975;9:324-34.
48. Chien S, Kaperonis AA, King RG, Lipowsky HH, Schmalzer EA, Sung LA, et al. Rheology of sickle cells and its role in microcirculatory dynamics. Prog Clin Biol Res 1987;240:151-65.
49. Telen MJ. Principles and problems of transfusion in sickle cell disease. Semin Hematol 2001;38:315-23.
50. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-90.
51. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin α in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-61.
52. Martino MA, Vogel KM, O'Brien SP, Kerstein MD. Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. J Am Coll Surg 1998;187:616-9.
53. Ataga K, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003;115:721-8.
54. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant 2005;20 suppl 4:3-8.
55. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351:1403-8.
56. Coumoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. The Canadian PRCA Focus Group. J Am Soc Nephrol 2004;15:2728-34.
57. Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-92.